Frontiers

Intercellular communication in chronic neuroinflammatory diseases

Neuroinflammation represents a hallmark of many degenerative diseases, such as Alzheimer’s Disease, Parkinson’s Disease, amyotrophic lateral sclerosis, multiple sclerosis, multiple system atrophy and ...
News On 6

Oklahoma man reaches remission after rare autoimmune brain disease diagnosis

An Oklahoma man is in full remission after doctors diagnosed a rare autoimmune brain disease following years of unexplained symptoms and misdiagnoses. An estimated 25 to 30 million Americans live with ...

ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) and other neurodegenerative disorders, today ...

ProMIS Neurosciences Inc.: ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease ...
Ophthalmology Times

PRIMA System: A major step in the battle against GA

“In GA, light is not transduced into electrical signals because of a loss of photoreceptors, which leads to an absolute scotoma (blind spot). 2,3 The PRIMA neurostimulation system replaces the lost ...
The Edge Singapore

Biogen’s profit forecast tops estimates on cost-cutting

Biogen Inc forecast 2026 profit above Wall Street’s expectations, signalling that steep cost-cutting measures are cushioning ...

Atrial Fibrillation: When chaos takes over heart’s rhythm

Inside the human chest, a tireless engine performs a rhythmic masterpiece roughly one hundred thousand times a day. If you ...
Pharmabiz

Roche’s phase III FENtrepid study of fenebrutinib meets its primary endpoint of non-inferiority compared to Ocrevus in reducing disability progression in patients with PPMS

Roche’s phase III FENtrepid study of fenebrutinib meets its primary endpoint of non-inferiority compared to Ocrevus in reducing disability progression in patients with PPMS ...
The Manila Times

Roche’s fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)

Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, OCREVUS, in ...

Is Moon City Possible In 10 Years? Here Are The Challenges Elon Musk Will Face

For a real 'Moon city' — meaning sustained human presence, infrastructure, and self-supporting life systems — SpaceX has a ...
Le Lézard

Genentech's Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS)

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new late-breaking data from the Phase III FENtrepid study showing the investigational Bruton's tyrosine kinase (BTK ...

ADARx Pharmaceuticals Appoints Donald Fong, M.D., as Chief Medical Officer

Seasoned clinical development leader brings more than 25 years of deep expertise in clinical development and operations across biotech and ...